| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
Third quarter 2026 revenue growth of 36% driven by strong performance in Oncology and Screening |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
PALO ALTO, Calif., — November 3, 2026 — Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and curre... |
| 03 Nov 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Guardant Health, Inc., a Delaware corporation (the “Company”), has granted to the participant listed below (“Participant”) the Performance-Based Restricted Stock Units (the “PSUs”) described in this Global Performance-Based Restricted St... |
| 30 Jul 2026 |
8-K: Results of Operations and Financial Condition
Second quarter 2026 revenue growth of 44% driven by strong performance in Oncology and Screening |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders (the “Annual Meeting”) of Guardant Health, Inc. (the “Company”) was held on June 17, 2026. |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
First quarter 2026 revenue growth of 48% driven by strong performance in Oncology and Screening |
| 27 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition
Fourth quarter 2025 revenue growth of 39% broadly driven by strong performance across Oncology and Screening |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Fourth quarter revenue growth of 39% driven by strong Oncology and Screening volume |
| 07 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of November 7, 2025, between Guardant Health, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). |
| 29 Oct 2025 |
8-K: Results of Operations and Financial Condition
Revenue growth of 39% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data |
| 24 Sep 2025 |
8-K: Regulation FD Disclosure
Guardant Health, Inc. (the “Company”) will host an Investor Day on September 24, 2025 beginning at 9:00 a.m. Eastern time in New York City. The presentation will include remarks from Helmy Eltoukhy and AmirAli Talasaz, co-Chief Executive... |
| 15 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
PALO ALTO, Calif., September 15, 2025 -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Alex M. Azar II to its board of directors, effective immediately. As the 24th Secretary... |
| 30 Jul 2025 |
8-K: Results of Operations and Financial Condition
Revenue growth of 31% broadly driven by strong performance across Oncology, Screening, and Biopharma & Data |
| 20 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The annual meeting of stockholders (the “Annual Meeting”) of Guardant Health, Inc. (the “Company”) was held on June 18, 2025. |
| 30 Apr 2025 |
8-K: Results of Operations and Financial Condition
Revenue growth of 21% broadly driven by strong performance across oncology, screening, and biopharma & data |
| 09 Apr 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
On April 3, 2025, Guardant Health, Inc. (the “Company”) entered into a third amendment to the lease (“Third Amendment”) dated November 1, 2014 between the Company and Metropolitan Life Insurance Company (the “Landlord”), as amended on Oc... |
| 20 Feb 2025 |
8-K: Results of Operations and Financial Condition
Full year 2024 total revenue growth of 31% driven by strong clinical oncology volume growth, Guardant360 ASP tailwinds, and product upgrades |
| 14 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
INDENTURE, dated as of February 14, 2025, between Guardant Health, Inc., a Delaware corporation, as issuer (the “Company”), and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). |
| 07 Feb 2025 |
8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
Guardant Health, Inc., a Delaware corporation, (the “Company”), is offering a new series of its Convertible Senior Notes due 2031 (the “New Notes”). The New Notes will be convertible into cash, shares (“Underlying Shares”) of common stoc... |
Loading...